As we enter 2021, global pharmaceutical markets are showing rapid growth driven by the increasing demand
for generic medicines and biologics due to a rise in population and the increasing incidence of disease around
the world. Due to the capital-intensive nature of the business, and complex manufacturing requirements, many
pharma and biopharma companies are partnering with contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) for clinical and commercial stage manufacturing as well as early development activities.
The biggest factor driving the growth of C(D)MOs in the pharmaceutical industry is the growing need for state-of-the-art processes and production technologies, which have proven highly effective in meeting regulatory requirements. However, factors such as stringent regulations and high logistics costs are restraining the market. The pharmaceutical contract manufacturing global market is expected to grow at mid-single-digits to reach $96 billion by 2025.
In 2021 Contract Pharma embarks on its 22nd year as the leading global media outlet dedicated to Pharma and Biopharma outsourcing. Since its debut back in November 1999, Contract Pharma has continued to evolve from its legacy roots in print growing into a full-service media outlet, expanding the brand across the digital landscape through ContractPharma.com, social media channels and video production. Entering its 21st year, Contract Pharma renews its commitment to being the premier media source dedicated to the Pharma and Biopharma outsourcing industry.